

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 August 2024 (22.08.2024)



(10) International Publication Number
WO 2024/169698 A1

(51) International Patent Classification:

C07D 263/22 (2006.01) A61P 3/10 (2006.01)
C07D 413/12 (2006.01) A61P 3/00 (2006.01)
A61K 31/421 (2006.01) A61P 9/00 (2006.01)
A61K 31/422 (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/CN2024/075822

(22) International Filing Date:

04 February 2024 (04.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/075624

13 February 2023 (13.02.2023) CN

(71) Applicant: **ALEBUND PHARMACEUTICALS
(HONG KONG) LIMITED** [CN/CN]; I/F., No. 50 Tai
Wan New Village, Yung Shue Wan, Lamma Island, Hong
Kong (CN).

(72) Inventors: **LI, Fang**; I/F., No. 50 Tai Wan New Village,
Yung Shue Wan, Lamma Island, Hong Kong (CN). **LI,
Jialiang**; I/F., No. 50 Tai Wan New Village, Yung Shue
Wan, Lamma Island, Hong Kong (CN). **SHU, Chutian**; I/
F., No. 50 Tai Wan New Village, Yung Shue Wan, Lamma
Island, Hong Kong (CN).

(74) Agent: **JUN HE LAW OFFICES**; 20/F, China Resources
Building 8 Jianguomenbei Avenue, Dongcheng District,
Beijing 100005 (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: CRYSTALLINE FORMS OR SALTS OF A DEUTERATED COMPOUND

(57) Abstract: The present disclosure relates to various crystalline forms of Compound 2 or salt of Compound 2, as well as pharmaceutical compositions, methods of making and methods of using the same. These crystalline forms are useful in the treatment of diseases and disorders which are modulated by PPAR α and/or PPAR γ agonists.

WO 2024/169698 A1